Comment from Association for Accessible Medicines

Summary: The Association for Accessible Medicines (AAM), representing generic and biosimilar pharmaceutical manufacturers, supports the draft guidance but requests more specific impurity thresholds and clearer guidance on its application to products currently under development. They argue that more detailed specifications are necessary to ensure regulatory consistency with international standards and to prevent supply chain disruptions.